Acute hypocalcaemia following denosumab in heart and lung transplant patients with osteoporosis

Background Osteoporosis is highly prevalent in the heart and lung transplant population. Given high rates of concurrent renal impairment, there is increasing use of denosumab in this population. However, denosumab may be associated with hypocalcaemia, particularly in patients with chronic kidney dis...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2018-06, Vol.48 (6), p.681-687
Main Authors: Shrosbree, Julia E., Elder, Grahame J., Eisman, John A., Center, Jacqueline R.
Format: Article
Language:English
Subjects:
25-Hydroxyvitamin D
Calcium
Calcium (blood)
denosumab
Glomerular filtration rate
Heart
Heart transplantation
hypocalcaemia
Hypocalcemia
Immunotherapy
Kidney transplantation
Lung transplantation
Monoclonal antibodies
Osteoporosis
Prednisone
transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Osteoporosis is highly prevalent in the heart and lung transplant population. Given high rates of concurrent renal impairment, there is increasing use of denosumab in this population. However, denosumab may be associated with hypocalcaemia, particularly in patients with chronic kidney disease (CKD). Aim To explore the risk of hypocalcaemia in a heart and lung transplant cohort prescribed denosumab for osteoporosis. Methods We performed a retrospective database review of all surviving heart and lung transplant patients who had received denosumab for osteoporosis between January 2012 and November 2015. We assessed the rates of hypocalcaemia in this cohort and collected baseline clinical data to determine associated factors. Results Ten patients received denosumab and had laboratory results available within 3 months of the dose. Of these, three patients developed severe (grade 4) hypocalcaemia, while two patients developed mild (grade 1) hypocalcaemia. In comparison to the five patients who remained normocalcaemic, patients with hypocalcaemia had significantly lower baseline mean estimated glomerular filtration rate but similar baseline mean corrected serum calcium. Unexpectedly, patients developing hypocalcaemia had non‐significantly higher levels of 25‐hydroxyvitamin D and lower baseline doses of prednisone. Conclusions In heart and lung transplant patients, denosumab should be used judiciously in patients with advanced renal disease due to the risk of hypocalcaemia.
ISSN:1444-0903
1445-5994
DOI:10.1111/imj.13744